Cutaneous T-Cell Lymphoma Market
DelveInsight’s ‘Cutaneous
T- Cell Lymphoma (CTCL) - Market Insights, Epidemiology and Market
Forecast-2028’ report delivers an in-depth understanding of the
disease, historical & forecasted epidemiology as well as the market trends
of Cutaneous T- Cell Lymphoma (CTCL) in the United States, EU5 (Germany, Spain,
Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices,
emerging drugs, market share of the individual therapies, current and
forecasted market size of Cutaneous T- Cell Lymphoma (CTCL) from 2017 to 2028
segmented by seven major markets. The Report also covers current treatment
practice/algorithm, market drivers, market barriers and unmet medical needs to
curate best of the opportunities and assess underlying potential of the market.
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Study
Period: 2017-2028
Cutaneous T-cell lymphoma (CTCL) is a group of lympho
proliferative disorders characterized by localization of neoplastic T
lymphocytes to the skin. Collectively, CTCL is classified as a type of
non-Hodgkin lymphoma (NHL). Cutaneous T-cell lymphomas (CTCL) are the most
common types of skin lymphoma. More than 3 out of every 4 skin lymphomas
diagnosed are CTCLs. They often appear as eczema-like skin rashes and can
affect widespread parts of the body. There are different subtypes of CTCL. The
most common type is mycosis fungoides. In some cases CTCL or Cutaneous T-Cell
Lymphoma can affect more than just the skin and cause formation of tumor,
exfoliation, and ulceration accompanied by infections and itching. In the
advanced stages CTCL or Cutaneous T-Cell Lymphoma begins to extend to lymph
nodes, internal organs and peripheral blood. CTCL or Cutaneous T-Cell Lymphoma
is not a life threatening disease and mostly it can be treated but not cured.
The DelveInsight Cutaneous T- Cell Lymphoma (CTCL) market
report gives a thorough understanding of the Cutaneous T- Cell Lymphoma (CTCL)
by including details such as disease definition, types, staging, causes,
pathophysiology, symptoms and diagnostic trends. It also provides treatment algorithms
and treatment guidelines for Cutaneous T- Cell Lymphoma (CTCL) in the United
States, EU5 (Germany, Spain, France, Italy, the UK) & Japan.
The Cutaneous T- Cell Lymphoma (CTCL) epidemiology
division provide the insights about historical and
current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted
trends by exploring numerous studies and views of key opinion leaders. This
part of the DelveInsight report also provides the diagnosed and treatable
patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented
by incident population, sub-type specific incident population,
gender-specific incidence population and stage specific incidence cases of
Cutaneous T- Cell Lymphoma (CTCL).
The DelveInsight report also provides the epidemiology
trends observed in the 7MM during the study period, along with the assumptions
undertaken. The calculated data are presented with relevant tables and graphs
to give a clear view of the epidemiology at first sight.
According to DelveInsight, the incident population of
Cutaneous T- Cell Lymphoma (CTCL) was estimated to be 8,617 [7MM] in
2018. United States accounts for the highest Cutaneous T- Cell Lymphoma
(CTCL) cases, followed by EU5 (Germany, France, Italy, Spain & UK) and
Japan. Among the EU5 countries UK had the highest prevalent patient population
of Cutaneous T- Cell Lymphoma (CTCL), followed by Germany.
This segment of the Cutaneous T- Cell Lymphoma
(CTCL) report encloses the detailed analysis of marketed drugs and
late stage (Phase-III) pipeline drugs. It also helps to understand the clinical
trial details, expressive pharmacological action, agreements and
collaborations, approval and patent details, advantages and disadvantages of
each included drug and the latest news and press releases.
There are currently seven approved therapies including Istodax,
Potelegio and Uvadex, which are being used for the
treatment of Cutaneous T- Cell Lymphoma (CTCL). However these drugs have shown
to be effective in managing the Cutaneous T- Cell Lymphoma (CTCL) by reducing
symptoms, risk of complications, and exacerbations among persons with CTCL.
Though there are treatments available for Cutaneous T Cell Lymphoma (CTCL) but
the available options are limited. There is no cure available for CTCL and the
available treatments are for management of CTCL. The patients are treated with
consecutive therapies until loss of response or without treatment ‘expectant
therapy’ if no suitable therapy is available. Detailed chapters for all of
these marketed drugs along with the other promising candidates like Adcetris and Zolinza have
also been covered in the report.
The Cutaneous T- Cell Lymphoma (CTCL) market
outlook of the report helps to build the detailed comprehension of the
historic, current and forecasted trend of the market by analyzing the impact of
current therapies on the market, unmet needs, drivers and barriers and demand
of better technology.
This segment gives a through detail of market trend of each
marketed drug and late-stage pipeline therapy by evaluating their impact based
on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of
action, compliance rate, growing need of the market, increasing patient pool,
covered patient segment, expected launch year, competition with other
therapies, brand value, their impact on the market and view of the key opinion
leaders. The calculated market data are presented with relevant tables and
graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Cutaneous T-
Cell Lymphoma (CTCL) was estimated to be USD 785.24 million in 2018.
The United States accounts for the largest market size of Cutaneous T- Cell
Lymphoma (CTCL), in comparison to EU5 (the United Kingdom, Germany, Italy,
France, and Spain), and Japan.
The dynamics of Cutaneous T- Cell Lymphoma (CTCL) market is
anticipated to change in the coming years owing to the expected launch of
emerging therapies during the forecasted period 2019-2028. Launch of potential
therapies may increase market size in the coming years, assisted by an increase
in diagnosed prevalent population of Cutaneous T- Cell Lymphoma (CTCL).
Upcoming therapies such as Soligenix’s SGX301, Janssen’s
Quisinostat and many more, have the potential to create a significant
positive shift in the Cutaneous T- Cell Lymphoma (CTCL) market size. The United
States accounts for the largest market size of Cutaneous T- Cell Lymphoma
(CTCL), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and
Spain), and Japan.
This section focusses on the rate of uptake of the potential
drugs recently launched in the market or will get launched in the market during
the study period from 2017-2028. The analysis covers market uptake by drugs;
patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid
uptake, reasons behind the maximal use of new drugs and allows the comparison
of the drugs on the basis of market share and size which again will be useful
in investigating factors important in market uptake and in making financial and
regulatory decisions.
The market size of Cutaneous T- Cell Lymphoma (CTCL)
includes the drug-uptake for individual therapies, which is further segmented
on the basis of market size and market share by Line of therapy and Route of
Administration.
To counter current unmet needs of the market and to provide
better treatment options for Cutaneous T- Cell Lymphoma (CTCL), several
companies are working robustly on developing new therapies with novel mechanism
of action.
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Cutaneous T- Cell Lymphoma (CTCL) market.
- Organize sales and marketing efforts by identifying the best opportunities for Cutaneous T- Cell Lymphoma (CTCL) market.
- To understand the future market competition in the Cutaneous T- Cell Lymphoma (CTCL) market.
Comments
Post a Comment